Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.51 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2872730 | 0.88 | PTGS2 (0.43) | PTGS2KMT2APTGS1MEP1BMAPK1 | |
| SCHEMBL1816396 | 0.85 | LMNA (0.55) | PTGS2KMT2AMAPK1POLBTSHR | |
| SCHEMBL29651875 | 0.85 | LMNA (0.55) | PTGS2KMT2AMAPK1POLBTSHR | |
| SCHEMBL806536 | 0.83 | PTGS2 (0.67) | PTGS2KMT2APTGS1MEP1BMAPK1 | |
| SCHEMBL29015043 | 0.83 | PTGS2 (0.54) | PTGS2KMT2APTGS1MEP1BMAPK1 | |
| SCHEMBL66188 | 0.82 | TSHR (0.70) | PTGS2KMT2APTGS1MAPK1POLB | |
| SCHEMBL647351 | 0.81 | MEP1B (0.55) | PTGS2KMT2APTGS1MEP1BMAPK1 | |
| SCHEMBL2121926 | 0.81 | PTGS2 (0.68) | PTGS2KMT2APTGS1 | |
| SCHEMBL28552857 | 0.81 | PTGS2 (0.53) | PTGS2KMT2APTGS1MEP1BMAPK1 | |
| SCHEMBL15209590 | 0.81 | PTGDR (0.43) | PTGS2KMT2APTGS1MEP1BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-11 | — | — | US | disclosed |
| US-20250011289-A1 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | J. MICHAEL BISHOP INSTITUTE OF CANCER RESEARCH (CN) | 2025-01-09 | — | — | US | disclosed |
| EP-4477220-A2 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-12-18 | — | — | EP | disclosed |
| CN-118525007-A | 1H-benzo [ B ] azepin-2 (3H) -one compounds, compositions and methods for treating cancer | 成都安泰康赛生物科技有限公司 | 2024-08-20 | — | — | CN | disclosed |
| EP-4031547-B1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-4031547-B1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| CN-117209501-A | Sulfonamide derivatives and uses thereof | 苏州朗睿生物医药有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230391773-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-07 | — | — | US | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1567502-A1 | SUBSTITUTED DIHYDROPHENANTHRIDINESUL FONAMIDES | Wyeth (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6894061-B2 | Substituted dihydrophenanthridinesulfonamides | WYETH (US) | 2005-05-17 | — | — | US | disclosed |
| EP-1230224-B1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2004-12-29 | — | — | EP | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| US-6821980-B1 | Substituted 5-benzyl-2,4-diaminopyrimidines | BASILEA PHARMACEUTICA AG (CH) | 2004-11-23 | — | — | US | disclosed |
| US-20040167155-A1 | Substituted dihydrophenanthridinesulfonamides | WYETH | 2004-08-26 | — | — | US | disclosed |
| WO-2004050631-A1 | SUBSTITUTED DIHYDROPHENANTHRIDINESUL FONAMIDES | WYETH (US) | 2004-06-17 | — | — | WO | disclosed |
| EP-1230224-A1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001032633-A1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | PTGS2 1962/4885KMT2A 1299/4885PTGS1 1185/4885 |
| US-20250011289-A1 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | BRCA1, TP53, BCCIP | PTGS2 303/4885KMT2A 1749/4885PTGS1 194/4885 |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | PTGS2 1962/4885KMT2A 1299/4885PTGS1 1185/4885 |
| US-20040167155-A1 | Substituted dihydrophenanthridinesulfonamides | TNNT2, TNNI3, SIRT5 | PTGS2 144/4885KMT2A 2994/4885PTGS1 230/4885 |
| US-20230391773-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | KLKB1, KLK1, KLK5 | PTGS2 1962/4885KMT2A 1299/4885PTGS1 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.